Floatz logo

Rgx-111

Hurler Syndrome

REGENXBIO Inc.gene_therapyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Hurler Syndrome cohort.

Asset / SponsorPhaseRating
Aldurazyme
Genzyme, a Sanofi Company
Phase 4A
IDURONIDASE, .ALPHA.-L-(8-HISTIDINE) (HUMAN)
Masonic Cancer Center, University of Minnesota
Phase 4BB
IDURONIDASE, .ALPHA.-L-(8-HISTIDINE) (HUMAN)
Masonic Cancer Center, University of Minnesota
Phase 4BB
Thiotepa
University of Florida
Phase 2BB
Cyclophosphamide
Masonic Cancer Center, University of Minnesota
Phase 2B

View all 14 →

Same molecule, other indications

Rgx-111 is also rated in:

mucopolysaccharidosis type 1Dormant
CCC
Indicative ·
48 / 100
View asset →
Hurler-Scheie syndromeDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →